NCT03027102已完成1 期
Phase I Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- Number of patients with adverse events and abnormal laboratory studies.
研究概览
简要总结
This study aims to determine the safety and toxicity of incremental doses of Double Negative T (DNT) cells in human subjects with high risk acute myeloid leukemia (AML). DNT cells are mature T lymphocytes that comprise ~1% of white blood cells in humans. Injection of DNTs from healthy donors has been demonstrated to be effective against AML cells. DNT cells will be collected from healthy volunteers and injected into patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients with AML who are 18 years of age or older.
- •Viably frozen cells from the time of diagnosis or relapse are available for sensitivity testing to DNT cells.
- •Patients have given informed consent.
- •Patients in remission following FLAG-Ida induction therapy who are receiving consolidation treatment.
- •Creatinine < 1.5 x ULN within 7 days prior to day 1 of study treatment.
- •AST, ALP, bilirubin < 1.5x ULN within 7 days prior to day 1 of study treatment.
- •Female patients of childbearing potential should be willing to use 2 methods of birth control (Refer to section 9.2.15 or be surgically sterile, or abstain from heterosexual activity for the course of the study from day 1 until 1 months following chemotherapy. Patients of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 2 years.
- •Male patients should use condoms or abstain from sex from the time of beginning chemotherapy to 1 month after the chemotherapy.
- •Patients must be able to comply with study procedures, at the minimum, until all DNT-UHN-1 cells are out of their system.
排除标准
- •ECOG performance status <
- •Patients with a known persistent infection.
- •Patients with known active CNS disease.
- •Life expectancy < 3 months.
- •Patients should be off Cox2 inhibitors and corticosteroids for at least 3 days prior to and 7 days after infusion of DNT cells.
- •Patients who are HIV positive.
- •Patients for whom healthy donor DNT kill <10% of patient's blast cells.
- •Donor Inclusion Criteria:
- •Has given written informed consent.
- •Is 18 years of age or older.
- •No known prior blood product transfusion or surgery.
- •Blood electrolytes (Sodium, Potassium, Chloride, Bicarbonate, Magnesium, Phosphate, Calcium) within normal ranges.
- •Normal complete blood counts.
- •Normal liver and kidney function (Bilirubin, AST, ALT, ALP, LDH, plasma albumin, creatinine).
- •Negative for transfusion transmissible illnesses (CMV, HIV I/II, HTLV I/II, Hepatitis B Surface Antigen, Hepatitis B Surface Antibody, Hepatitis B Core Antibody, Hepatitis C Antibody) within 30 days of blood collection for DNT cell expansion for patient infusion.
- •Negative for evidence of exposure to West Nile Virus, Syphilis within 30 days of blood collection for DNT cell expansion for patient infusion.
- •DNT cell expansion yield is >108 per mL blood using the standard protocol. Expanded DNT cells show ≥20% cytotoxicity to at least 3 AML cell lines (MV4-11 AML3, and U937).
- •The donor who meet all donor inclusion/exclusion criteria, whose DNT cells show the most potent killing (minimum >10% killing) of AML patient's blast cells (blast cells frozen at time of diagnosis or relapse) will be approached for participation in this study.
- •Donor Exclusion Criteria:
- •With a history of high risk behavior including, but not limited to, a history of piercing (except ear lobes), tattoos or other body modification.
- •Has serious illnesses such as cardiovascular disease & cancer.
- •Has sexually transmissible disease.
- •Has history of intravenous drug use.
- •Persons who received any vaccinations in past 3 months prior to enrolment into this study.
- •Persons who travel outside the U.S. and Canada in the past 3 years prior to enrolment into this study, to areas that are considered endemic for malaria.
- •Persons who have received blood components or other human tissues in the past 12 months prior to enrolment into this study (however this may be reduced to 6 months if nucleic acid testing (NAT) is used for the tests).
- •Pregnant or lactating.
- •Persons at risk of transmitting a hematological or immunological disease.
- •Persons with transmissible genetic diseases in the family.
- •On prescription medication.
- •Persons with prion-related disease.
- •Persons with a neurological disease of an unestablished etiology.
- •Persons with active encephalitis or meningitis of infectious or unknown etiology.
- •Persons with rabies or persons who, within the past 6 months, were bitten by an animal and treated as if the animal was rabid.
- •Persons with a family history of Creutzfeldt-Jakob disease.
- •Persons who have received human-derived pituitary growth hormone or dura mata.
- •Persons who have known or suspected sepsis at the time of donation.
研究组 & 干预措施
Patient Arm
Experimental
Patients will receive DNT cells from healthy donors.
干预措施: DNT cells (Biological)
结局指标
主要结局
Number of patients with adverse events and abnormal laboratory studies.
时间窗: 2 years
Patients will be assessed for adverse events based upon, but not limited to, monitoring of vital signs and prescribed laboratory studies. Adverse events (AE) will use the descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE). This study will utilize the CTCAE Version 4.03 for adverse event reporting.
次要结局
- Leukemia load(2 years)
- Number of cells with disease specific mutations per patient(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
CD19 CAR T Cells for B Cell Malignancies After Allogeneic TransplantPhiladelphia Chromosome Negative Adult Precursor Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Adult Precursor Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Mantle Cell LymphomaRefractory Chronic Lymphocytic LeukemiaNCT01475058Fred Hutchinson Cancer Center1
尚未招募
1 期
Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)CoronavirusSARS-CoV-2 InfectionCOVID-19NCT05633446Gylden Pharma Ltd110
招募中
1 期
Safety Study for a Gamma Delta T Cell Product Used with Low Dose Radiotherapy in Patients with Locally Advanced or Metastatic NSCLC or Solid Tumors with Bone MetastasesNCT06069570Kiromic BioPharma Inc.48
进行中（未招募）
1 期
T-Cell Therapy for Advanced Breast CancerMetastatic HER2-negative BreastBreast CancerNCT02792114Memorial Sloan Kettering Cancer Center186
招募中
1 期
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)Solid TumorNCT05798533BGI, China6